U.S. markets closed

Integra LifeSciences Holdings Corporation (IART)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.95+1.43 (+3.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close45.52
Bid42.00 x 800
Ask47.25 x 1000
Day's Range45.20 - 46.99
52 Week Range34.21 - 63.23
Avg. Volume459,310
Market Cap3.957B
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateOct 22, 2020 - Oct 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is Integra (IART) Down 11.6% Since Last Earnings Report?

    Why Is Integra (IART) Down 11.6% Since Last Earnings Report?

    Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Integra LifeSciences Announces September 2020 Investor Conference Schedule

    PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it will participate in two investor conferences in September. * On September 10, 2020, Carrie Anderson, chief financial officer will present at the Wells Fargo 2020 Virtual Healthcare Conference at 9:20am ET.   * On September 14, 2020, Peter Arduini, president and chief executive officer will present at the Morgan Stanley Virtual Global Healthcare Conference at 10:30am ET.Both presentations will be webcast on the Integra LifeSciences investor relations website at http://investor.integralife.com/events-and-presentations.About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru®.  For the latest news and information about Integra and its brands, please visit www.integralife.com.Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2019 and information contained in subsequent filings with the Securities and Exchange Commission, including, without limitation, Integra’s Report on Form 10-Q filed on August 10, 2020, could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contacts: Michael Beaulieu Director, Investor Relations (609) 750-2827 michael.beaulieu@integralife.comMedia Contact: Laurene Isip Senior Director, Global Corporate Communications (609) 750-7984 laurene.isip@integralife.com

  • Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

    Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

    Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.